The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | WM-NET: upcoming clinical trials to advance the treatment of WM
Gottfried von Keudell, MD, Beth Israel Deaconess Medical Center, Boston, MA, discusses the Waldenström’s macroglobulinemia network (WM-NET), a U.S. initiative with the goal of advancing clinical trials of WM. Dr von Keudell mentions several upcoming trials by WM-NET, including the ZEBRA trial, which will investigate the combination of zanubrutinib, bendamustine, and rituximab. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
